Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02943317 · ClinicalTrials.gov registry record · Phase 1
Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer
A Phase 1 study, sponsored by Verastem.
- Terminated
- Registry status
- Phase 1
- Development phase
- 98
- Enrollment target
NCT02943317 is a Phase 1 study that was terminated before completion, run by Verastem. The registered enrollment target is 98 participants.
The verdict
NCT02943317, a Phase 1 study, was terminated before completion, sponsored by Verastem.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 98 participants
- Enrollment target
Study Summary
This is a Phase 1/1b, open-label, multicenter, dose-escalation and dose expansion trial to evaluate the safety, efficacy, PK and PD of defactinib (VS-6063) in combination with avelumab in epithelial ovarian cancer.
Interventions
- DRUG Part A - VS-6063
- DRUG Part A - Avelumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2016-10 |
| Est. Completion | 2018-12-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02943317
The ClinicalTrials.gov registry entry for NCT02943317 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Verastem, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Part A - VS-6063 is the first listed.
NCT02943317 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02943317 about?
NCT02943317 is a clinical study titled "Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer". This is a Phase 1/1b, open-label, multicenter, dose-escalation and dose expansion trial to evaluate the safety, efficacy, PK and PD of defactinib (VS-6063) in combination with avelumab in epithelial ovarian cancer.
What is the current status of trial NCT02943317?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 98 participants. The study started on 2016-10. Estimated completion is 2018-12-28.
What interventions are being tested in trial NCT02943317?
The interventions under investigation include: Part A - VS-6063 (DRUG), Part A - Avelumab (DRUG).
Who is sponsoring clinical trial NCT02943317?
This trial is sponsored by Verastem, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.